间隔6周mpMRI扫描在前列腺癌PI-RADS分类中的差异

IF 2.2 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Tomography Pub Date : 2025-08-18 DOI:10.3390/tomography11080092

Justine Schoch, Viola Düring, Michael Wiedmann, Daniel Overhoff, Daniel Dillinger, Stephan Waldeck, Hans-Ulrich Schmelz, Tim Nestler

{"title":"间隔6周mpMRI扫描在前列腺癌PI-RADS分类中的差异","authors":"Justine Schoch, Viola Düring, Michael Wiedmann, Daniel Overhoff, Daniel Dillinger, Stephan Waldeck, Hans-Ulrich Schmelz, Tim Nestler","doi":"10.3390/tomography11080092","DOIUrl":null,"url":null,"abstract":"Objectives: This study aimed to investigate the consistency of lesion identification by Prostate Imaging Reporting and Data System (PI-RADS) and the related clinical and histological characteristics in a high-volume tertiary care center.Materials and methods: The analysis used real-world data from 111 patients between 2018 and 2022. Each patient underwent two multiparametric magnetic resonance imaging (MRI) scans of the prostate at different institutions with a median interval of 42 days between the scans, followed by an MRI-fused biopsy conducted 7 days after the second MRI.Results: The PI-RADS classifications assigned to the index lesions in the in-house prostate MRI were as follows: PI-RADS V, 33.3% (n = 37); PI-RADS IV, 49.5% (n = 55); PI-RADS III, 12.6% (n = 14); and PI-RADS II, 4.5% (n = 5). Cancer detection rates for randomized and/or targeted biopsies were 91.9% (n = 34) for PI-RADS V, 65.5% (n = 36) for PI-RADS IV, 21.4% (n = 3) for PI-RADS III, and 20% (n = 1) for PI-RADS II. Overall, malignant histology was observed in 64.9% (n = 72) of the targeted lesions and 57.7% (n = 64) of the randomized biopsies. In the first performed, external MRI, 18% (n = 20) and 10.8% (n = 12) of the patients were classified in the higher and lower PI-RADS categories, respectively. The biopsy plan was adjusted for 57 patients (51.4%); nevertheless, any cancer could have possibly been identified regardless of the adjustments.Conclusion: The 6-week interval between the MRI scans did not affect the quality of the biopsy results significantly.","PeriodicalId":51330,"journal":{"name":"Tomography","volume":"11 8","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390117/pdf/","citationCount":"0","resultStr":"{\"title\":\"Differences in PI-RADS Classification of Prostate Cancer Based on mpMRI Scans Taken 6 Weeks Apart.\",\"authors\":\"Justine Schoch, Viola Düring, Michael Wiedmann, Daniel Overhoff, Daniel Dillinger, Stephan Waldeck, Hans-Ulrich Schmelz, Tim Nestler\",\"doi\":\"10.3390/tomography11080092\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives: This study aimed to investigate the consistency of lesion identification by Prostate Imaging Reporting and Data System (PI-RADS) and the related clinical and histological characteristics in a high-volume tertiary care center.Materials and methods: The analysis used real-world data from 111 patients between 2018 and 2022. Each patient underwent two multiparametric magnetic resonance imaging (MRI) scans of the prostate at different institutions with a median interval of 42 days between the scans, followed by an MRI-fused biopsy conducted 7 days after the second MRI.Results: The PI-RADS classifications assigned to the index lesions in the in-house prostate MRI were as follows: PI-RADS V, 33.3% (n = 37); PI-RADS IV, 49.5% (n = 55); PI-RADS III, 12.6% (n = 14); and PI-RADS II, 4.5% (n = 5). Cancer detection rates for randomized and/or targeted biopsies were 91.9% (n = 34) for PI-RADS V, 65.5% (n = 36) for PI-RADS IV, 21.4% (n = 3) for PI-RADS III, and 20% (n = 1) for PI-RADS II. Overall, malignant histology was observed in 64.9% (n = 72) of the targeted lesions and 57.7% (n = 64) of the randomized biopsies. In the first performed, external MRI, 18% (n = 20) and 10.8% (n = 12) of the patients were classified in the higher and lower PI-RADS categories, respectively. The biopsy plan was adjusted for 57 patients (51.4%); nevertheless, any cancer could have possibly been identified regardless of the adjustments.Conclusion: The 6-week interval between the MRI scans did not affect the quality of the biopsy results significantly.\",\"PeriodicalId\":51330,\"journal\":{\"name\":\"Tomography\",\"volume\":\"11 8\",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390117/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tomography\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/tomography11080092\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tomography","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/tomography11080092","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

摘要

目的：本研究旨在探讨前列腺影像学报告和数据系统（PI-RADS）在大容量三级医疗中心病变识别的一致性以及相关的临床和组织学特征。材料和方法：该分析使用了2018年至2022年间111名患者的真实数据。每位患者在不同的机构接受两次多参数磁共振成像（MRI）前列腺扫描，扫描间隔中位数为42天，然后在第二次MRI后7天进行MRI融合活检。结果：PI-RADS对内部前列腺MRI指数病变的分级如下：PI-RADS V， 33.3% (n = 37)；PI-RADS IV, 49.5% (n = 55)；PI-RADS III, 12.6% (n = 14)；PI-RADS II为4.5% （n = 5）。随机和/或靶向活检的癌症检出率PI-RADS V为91.9% (n = 34)， PI-RADS IV为65.5% (n = 36)， PI-RADS III为21.4% (n = 3)， PI-RADS II为20% （n = 1）。总体而言，64.9% （n = 72）的目标病变和57.7% （n = 64）的随机活检中观察到恶性组织学。首次行外MRI时，分别有18% （n = 20）和10.8% （n = 12）的患者被划分为PI-RADS高、低两类。57例（51.4%）患者调整了活检计划；然而，无论如何调整，任何癌症都有可能被发现。结论：MRI扫描之间的6周间隔对活检结果的质量没有显著影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Differences in PI-RADS Classification of Prostate Cancer Based on mpMRI Scans Taken 6 Weeks Apart.

查看原文本刊更多论文

Differences in PI-RADS Classification of Prostate Cancer Based on mpMRI Scans Taken 6 Weeks Apart.

Objectives: This study aimed to investigate the consistency of lesion identification by Prostate Imaging Reporting and Data System (PI-RADS) and the related clinical and histological characteristics in a high-volume tertiary care center.

Materials and methods: The analysis used real-world data from 111 patients between 2018 and 2022. Each patient underwent two multiparametric magnetic resonance imaging (MRI) scans of the prostate at different institutions with a median interval of 42 days between the scans, followed by an MRI-fused biopsy conducted 7 days after the second MRI.

Results: The PI-RADS classifications assigned to the index lesions in the in-house prostate MRI were as follows: PI-RADS V, 33.3% (n = 37); PI-RADS IV, 49.5% (n = 55); PI-RADS III, 12.6% (n = 14); and PI-RADS II, 4.5% (n = 5). Cancer detection rates for randomized and/or targeted biopsies were 91.9% (n = 34) for PI-RADS V, 65.5% (n = 36) for PI-RADS IV, 21.4% (n = 3) for PI-RADS III, and 20% (n = 1) for PI-RADS II. Overall, malignant histology was observed in 64.9% (n = 72) of the targeted lesions and 57.7% (n = 64) of the randomized biopsies. In the first performed, external MRI, 18% (n = 20) and 10.8% (n = 12) of the patients were classified in the higher and lower PI-RADS categories, respectively. The biopsy plan was adjusted for 57 patients (51.4%); nevertheless, any cancer could have possibly been identified regardless of the adjustments.

Conclusion: The 6-week interval between the MRI scans did not affect the quality of the biopsy results significantly.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Tomography Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

2.70

自引率

10.50%

发文量

222

期刊介绍： TomographyTM publishes basic (technical and pre-clinical) and clinical scientific articles which involve the advancement of imaging technologies. Tomography encompasses studies that use single or multiple imaging modalities including for example CT, US, PET, SPECT, MR and hyperpolarization technologies, as well as optical modalities (i.e. bioluminescence, photoacoustic, endomicroscopy, fiber optic imaging and optical computed tomography) in basic sciences, engineering, preclinical and clinical medicine. Tomography also welcomes studies involving exploration and refinement of contrast mechanisms and image-derived metrics within and across modalities toward the development of novel imaging probes for image-based feedback and intervention. The use of imaging in biology and medicine provides unparalleled opportunities to noninvasively interrogate tissues to obtain real-time dynamic and quantitative information required for diagnosis and response to interventions and to follow evolving pathological conditions. As multi-modal studies and the complexities of imaging technologies themselves are ever increasing to provide advanced information to scientists and clinicians. Tomography provides a unique publication venue allowing investigators the opportunity to more precisely communicate integrated findings related to the diverse and heterogeneous features associated with underlying anatomical, physiological, functional, metabolic and molecular genetic activities of normal and diseased tissue. Thus Tomography publishes peer-reviewed articles which involve the broad use of imaging of any tissue and disease type including both preclinical and clinical investigations. In addition, hardware/software along with chemical and molecular probe advances are welcome as they are deemed to significantly contribute towards the long-term goal of improving the overall impact of imaging on scientific and clinical discovery.